Hemogenyx Pharmaceuticals PLC
HEMO
Company Profile
Business description
Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. The company is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
Contact
6 Heddon Street
LondonW1B 4BT
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
16
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,175.10 | 49.90 | 0.61% |
| CAC 40 | 7,543.86 | 41.08 | 0.55% |
| DAX 40 | 22,241.33 | 176.82 | 0.80% |
| Dow JONES (US) | 40,093.40 | 486.83 | 1.23% |
| FTSE 100 | 8,427.66 | 20.22 | 0.24% |
| HKSE | 21,980.74 | 70.98 | 0.32% |
| NASDAQ | 17,166.04 | 457.99 | 2.74% |
| Nikkei 225 | 35,705.74 | 666.59 | 1.90% |
| NZX 50 Index | 12,017.84 | 61.37 | 0.51% |
| S&P 500 | 5,484.77 | 0.00 | 0.00% |
| S&P/ASX 200 | 7,968.20 | 47.70 | 0.60% |
| SSE Composite Index | 3,295.06 | 2.23 | -0.07% |